ArticleRespirology case reports2026
The First Documented Case of Congenital Drug-Resistant Tuberculosis in Indonesia: A Case Report.
Article in Respirology case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The First Documented Case of Congenital Drug-Resistant Tuberculosis in Indonesia: A Case Report.Respirology case reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Congenital drug-resistant tuberculosis (DR-TB) is a rare condition with no standardized treatment. Congenital TB itself is a life-threatening condition. The clinical manifestations can be nonspecific, particularly in preterm infants, which can further reduce diagnostic awareness. We report a case of a 32-week preterm baby with rifampicin-resistant TB. She was born with respiratory distress and early-onset jaundice, initially suspected of sepsis and admitted to the NICU. The infant initially showed clinical improvement at 3 days of life, but at 23 days of life, the clinical condition worsened despite a sterile blood culture. The mother was subsequently diagnosed with miliary TB with rifampicin-resistant Xpert sputum. The infant's gastric lavage Xpert MTB/RIF confirmed rifampicin-resistant TB. At 32 days of life, she received a five-drug regimen, including bedaquiline. She completed 12 months of treatment with a favourable outcome. This case highlights the challenges of early recognition and treatment selection in congenital DR-TB.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.